{"symbol":"SH603367","secucode":"603367.SH","items":[{"title":"【概念速递】辰欣药业新增“创新药”概念","summary":"2026年7月15日，辰欣药业新增“创新药”概念。入选理由：2025年年报显示，公司坚持“高端仿制药、OTC外用药、创新药、特医食品”四轮驱动战略，产品矩阵涵盖慢性病、抗感染、心脑血管、肿瘤、消化系统及罕见病等多个治疗领域，形成了全生命周期健康管理解决方案，能够满足不同患者群体从预防、治疗到康复的多层次、多样化用药需求。","source":null,"url":"http://stock.eastmoney.com/news/11669,202607153807432228.html","info_code":"NW202607153807432228","show_time_timestamp":1784101959000,"show_time":"2026-07-15 15:52:39","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://stock.eastmoney.com/a/202607153807432228.html","url":"http://stock.eastmoney.com/news/11669,202607153807432228.html","code":"202607153807432228","infoCode":"NW202607153807432228","recordId":null,"source":null,"title":"【概念速递】辰欣药业新增“创新药”概念","updateTime":0,"showDateTime":1784101959000,"publishDate":0,"sRatingName":null,"summary":"2026年7月15日，辰欣药业新增“创新药”概念。入选理由：2025年年报显示，公司坚持“高端仿制药、OTC外用药、创新药、特医食品”四轮驱动战略，产品矩阵涵盖慢性病、抗感染、心脑血管、肿瘤、消化系统及罕见病等多个治疗领域，形成了全生命周期健康管理解决方案，能够满足不同患者群体从预防、治疗到康复的多层次、多样化用药需求。"}},{"title":"上半年对外授权创新高！A股创新药板块拉升，迪哲医药20cm涨停","summary":"7月14日，A股创新药板块拉升明显。迪哲医药（688192.SH）直线拉升至20%涨停。此外，陇神戎发（300534.SZ）、ST南新（688189.SH）等收涨超10%，联化科技（002250.SZ）、辰欣药业（603367.SH）、哈药股份（600664.SH）、济民健康（603222.SH）等涨停，其中哈药股份实现三天三板。创新药上游CXO板块也上涨明显。","source":null,"url":"http://stock.eastmoney.com/news/1406,202607143805654593.html","info_code":"NW202607143805654593","show_time_timestamp":1784018880000,"show_time":"2026-07-14 16:48:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202607143805654593.html","url":"http://stock.eastmoney.com/news/1406,202607143805654593.html","code":"202607143805654593","infoCode":"NW202607143805654593","recordId":null,"source":null,"title":"上半年对外授权创新高！A股创新药板块拉升，迪哲医药20cm涨停","updateTime":0,"showDateTime":1784018880000,"publishDate":0,"sRatingName":null,"summary":"7月14日，A股创新药板块拉升明显。迪哲医药（688192.SH）直线拉升至20%涨停。此外，陇神戎发（300534.SZ）、ST南新（688189.SH）等收涨超10%，联化科技（002250.SZ）、辰欣药业（603367.SH）、哈药股份（600664.SH）、济民健康（603222.SH）等涨停，其中哈药股份实现三天三板。创新药上游CXO板块也上涨明显。"}},{"title":"14秒，垂直涨停","summary":"7月14日午后，创新药概念异动拉升。个股方面，迪哲医药直线拉升，仅用14秒，封“20CM”涨停，最新市值262.03亿元。此外，哈药股份涨停，实现3连板，辰欣药业、联化科技涨停。消息面上，迪哲医药7月14日公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康（AZN）在全球范围内的独家开发、商业化舒沃哲的权利。","source":null,"url":"http://finance.eastmoney.com/news/1354,202607143805447435.html","info_code":"NW202607143805447435","show_time_timestamp":1784009160000,"show_time":"2026-07-14 14:06:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202607143805447435.html","url":"http://finance.eastmoney.com/news/1354,202607143805447435.html","code":"202607143805447435","infoCode":"NW202607143805447435","recordId":null,"source":null,"title":"14秒，垂直涨停","updateTime":0,"showDateTime":1784009160000,"publishDate":0,"sRatingName":null,"summary":"7月14日午后，创新药概念异动拉升。个股方面，迪哲医药直线拉升，仅用14秒，封“20CM”涨停，最新市值262.03亿元。此外，哈药股份涨停，实现3连板，辰欣药业、联化科技涨停。消息面上，迪哲医药7月14日公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康（AZN）在全球范围内的独家开发、商业化舒沃哲的权利。"}},{"title":"【直击涨停】创新药赛道爆发，迪哲医药直线“20CM”涨停","summary":"7月14日午后，创新药概念午后异动拉升，迪哲医药直线拉升“20CM”涨停。截至发稿，迪哲医药报56.33元/股，总市值约262亿元。此外，哈药股份斩获3连板，辰欣药业涨停，艾迪药业、甘李药业、赛伦生物等也大涨。消息面上，迪哲医药今日午间发布公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康（AZN）在全球范围内的独家开发、商业化舒沃哲的权利。","source":null,"url":"http://finance.eastmoney.com/news/1354,202607143805436038.html","info_code":"NW202607143805436038","show_time_timestamp":1784008385000,"show_time":"2026-07-14 13:53:05","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202607143805436038.html","url":"http://finance.eastmoney.com/news/1354,202607143805436038.html","code":"202607143805436038","infoCode":"NW202607143805436038","recordId":null,"source":null,"title":"【直击涨停】创新药赛道爆发，迪哲医药直线“20CM”涨停","updateTime":0,"showDateTime":1784008385000,"publishDate":0,"sRatingName":null,"summary":"7月14日午后，创新药概念午后异动拉升，迪哲医药直线拉升“20CM”涨停。截至发稿，迪哲医药报56.33元/股，总市值约262亿元。此外，哈药股份斩获3连板，辰欣药业涨停，艾迪药业、甘李药业、赛伦生物等也大涨。消息面上，迪哲医药今日午间发布公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康（AZN）在全球范围内的独家开发、商业化舒沃哲的权利。"}},{"title":"创新药概念午后异动拉升","summary":"创新药概念午后异动拉升","source":null,"url":"http://stock.eastmoney.com/news/1406,202607143805371413.html","info_code":"NW202607143805371413","show_time_timestamp":1784006126000,"show_time":"2026-07-14 13:15:26","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202607143805371413.html","url":"http://stock.eastmoney.com/news/1406,202607143805371413.html","code":"202607143805371413","infoCode":"NW202607143805371413","recordId":null,"source":null,"title":"创新药概念午后异动拉升","updateTime":0,"showDateTime":1784006126000,"publishDate":0,"sRatingName":null,"summary":"创新药概念午后异动拉升"}}]}